AI assistant
Sending…
Insight Molecular Diagnostics Inc. — Director's Dealing 2025
Mar 28, 2025
34238_dirs_2025-03-28_4d4a7c1f-b9ed-4b13-ad9d-69004ff48af3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Oncocyte Corp (OCX)
CIK: 0001642380
Period of Report: 2025-03-26
Reporting Person: Riggs Josh (CEO and President)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-03-26 | Restricted Stock Units | $0 | A | 188679 | Acquired | Common Stock (188679) | Direct |
Footnotes
F1: 25% of the restricted stock units will vest on each of the one-, two-, three- and four-year anniversaries, respectively, of the effective date of grant subject to continuous service through the applicable vesting date.
More from Insight Molecular Diagnostics Inc.
Annual Report
2026
Apr 30
Regulatory Filings
2026
Apr 30
Regulatory Filings
2026
Feb 26
Director's Dealing
2026
Feb 12
Major Shareholding Notification
2026
Feb 12
Regulatory Filings
2026
Feb 12
Regulatory Filings
2026
Feb 11
Regulatory Filings
2026
Feb 11
Director's Dealing
2025
Nov 13
Interim / Quarterly Report
2025
Nov 10